Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Guo He Lin"'
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundFor patients with anaplastic thyroid cancer (ATC) without mutational driver genes, chemotherapy is suggested to be the first-line treatment option. However, the benefits of chemotherapy in treating ATC are limited. In this analysis, we coll
Externí odkaz:
https://doaj.org/article/251e2e7c0f9f4df4987a09cde7f50c48
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundTyrosine kinase inhibitors (TKIs) contribute to the treatment of patients with anaplastic thyroid cancer (ATC). Although prospective clinical studies of TKIs exhibit limited efficacy, whether ATC patients benefit from TKI treatment in real-
Externí odkaz:
https://doaj.org/article/e369634cb7b840cb962a6c6dded54602
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundAdebrelimab showed excellent efficacy in the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, whether adebrelimab is superior to durvalumab and atezolizumab remains unclear. Therefore, we, in this study, a
Externí odkaz:
https://doaj.org/article/1f56a282db724f648fc48afdc15316be
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Highlights 1. Nearly 44% of relapsed Ewing sarcoma patients achieved an ORR after IT treatment. 2. Relapsed Ewing sarcoma treated with IT had an over 66% DCR. 3. IT chemotherapy caused low incidences of neutropenia, thrombocytopenia, and diarrhea in
Externí odkaz:
https://doaj.org/article/d79cff8793fb41fe9ecb551c7a9f6990
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAdding induction chemotherapy to concurrent platinum-based chemoradiotherapy has significantly prolonged the survival time of patients with locoregionally advanced nasopharyngeal carcinoma. In this study, we intend to evaluate the survival
Externí odkaz:
https://doaj.org/article/19c61ccc8a5d4f5b953141a17f90f636
Publikováno v:
Medicine; 8/2/2024, Vol. 103 Issue 31, p1-6, 6p
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Induction chemotherapy (IC) combined with concurrent chemoradiotherapy (CCRT) has been recommended as the first-line therapy for locoregional nasopharyngeal carcinoma (NPC). Due to the different chemotherapeutic drugs used in the
Externí odkaz:
https://doaj.org/article/bb1bcede1554416799f4e68326b8faee
Publikováno v:
PLoS ONE, Vol 17, Iss 10 (2022)
Background Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy is the standard of care in treating advanced non-small cell lung cancer (NSCLC). Nevertheless, whether adding pemetrexed-based chemotherapy to EGFR-TKI tar
Externí odkaz:
https://doaj.org/article/7e7e6e0e66164578a661c56d0d6ef943
Autor:
Zhan-Jie Zhang, Liang-Liang Shi, Xiao-Hua Hong, Bo-Ya Xiao, Guo-He Lin, Quentin Liu, Bi-Cheng Wang
Publikováno v:
PLoS ONE, Vol 17, Iss 3 (2022)
Background The major aim of this Bayesian network analysis was to determine the optimal treatment strategy for locoregionally advanced nasopharyngeal carcinoma (LANPC). Method We systematically searched databases and extracted data from randomized cl
Externí odkaz:
https://doaj.org/article/76eb9ee6f82e4a37a72159083a7c9986
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundDoxorubicin/Adriamycin (ADM) alone or combined with ifosfamide (IFO) (AI) is available for previously untreated advanced soft tissue sarcoma (ASTS). However, the clinical choice between them remains controversial. In this pooled analysis, w
Externí odkaz:
https://doaj.org/article/347e99729698474a8b7580c3e69c2cb8